Engineering Antibodies for Therapy
- 1 December 1992
- journal article
- Published by Wiley in Immunological Reviews
- Vol. 130 (1), 5-40
- https://doi.org/10.1111/j.1600-065x.1992.tb01519.x
Abstract
Click on the article title to read more.Keywords
This publication has 130 references indexed in Scilit:
- Crystal structure of a chimeric Fab′ fragment of an antibody binding tumour cellsJournal of Molecular Biology, 1992
- A humanized monovalent CD3 antibody which can activate homologous complementEuropean Journal of Immunology, 1991
- Crystallization and preliminary X-ray diffraction study of a chimaeric Fab′ fragment of antibody binding tumour cellsJournal of Molecular Biology, 1991
- Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1990
- Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulinsJournal of Molecular Biology, 1990
- Production of antibodies in transgenic plantsNature, 1989
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989
- Expression of an antibody Fv fragment in myeloma cellsJournal of Molecular Biology, 1988
- Canonical structures for the hypervariable regions of immunoglobulinsJournal of Molecular Biology, 1987
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986